Table 3 Medication use at enrollment by the patients enrolled in the CARRA Registry in the first 12 months of operation
Medication | Number (%) of Current Users | Number (%) of Ever Users |
|---|---|---|
Methotrexate | 556 (47%) | 868 (73%) |
Leflunomide | 52 (4%) | 71 (6%) |
Sulfasalazine | 20 (2%) | 49 (4%) |
Hydroxychloroquine | 49 (4%) | 69 (6%) |
Adalimumab | 140 (12%) | 235 (20%) |
Etanercept | 273 (23%) | 505 (42%) |
Golimumab | 7 (1%) | 13 (1%) |
Infliximab | 44 (4%) | 95 (8%) |
Any TNFi | 465 (39%) | 664 (56%) |
Any TNFi + Methotrexate | 255 (21%) | n/a |
Abatacept | 17 (1%) | 55 (5%) |
Tocilizumab | 59 (5%) | 115 (10%) |
Tocilizumab + Methotrexate | 42 (4%) | n/a |
Anakinra | 24 (2%) | 75 (6%) |
Canakinumab | 29 (2%) | 46 (4%) |
Any IL-1 inhibitor + Methotrexate | 18 (2%) | n/a |
Rituximab | 3 (<1%) | 16 (1%) |
Oral glucocorticoids | 124 (10%) | 560 (47%) |